Program
trastuzumab deruxtecan
Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.
Drug pageTrastuzumab deruxtecan: every studyAll 120 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyoits history only | 2611 open or running | phase 3since Apr 13, 2018 | Sep 21, 2015 | Oct 1, 2027phase 3 · NCT05950945 |
| AstraZeneca | 2120 open or running | phase 4since May 21, 2024 | Sep 22, 2017 | Feb 10, 2027phase 2 · NCT06271837 |
| Pfizerits history only | 10 open or running | phase 2since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| Strata Oncologyits history only | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Parexel, Merck, Bristol-Myers Squibb and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 8 earlier studies, Sep 22, 2017 to Oct 26, 2020.
- Dec 9, 2016Named trastuzumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 116
- Dec 8, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04686305 · 304 planned · United States, Australia, Belgium and more
- Jan 20, 2021Phase 3 study in Breast NeoplasmsNCT04739761 · 506 enrolled · United States, Australia, Belgium and more
- Feb 19, 2021Phase 3 study in Breast NeoplasmsNCT04784715 · 1,157 enrolled · United States, Argentina, Belgium and more
- Jul 14, 2021Phase 2 study in AdenocarcinomaNCT04989816 · 95 enrolled · China
- Sep 9, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05048797 · 454 enrolled · United States, Austria, Belgium and more
- Oct 22, 2021Phase 3 study in Breast NeoplasmsNCT05113251 · 927 enrolled · United States, Brazil, Bulgaria and more
- Feb 11, 2022Phase 2 study in HER2-mutant Non-Small Cell Lung CancerNCT05246514 · 72 enrolled · China
- Jan 19, 2024Phase 2 study in Breast NeoplasmsNCT06271837 · 127 enrolled · China
- May 21, 2024Phase 3 study in Biliary Tract NeoplasmsNCT06467357 · 620 planned · United States, Australia, Austria and more
- May 21, 2024Phase 4 study in Breast NeoplasmsNCT06429761 · 100 enrolled · India
- Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerNCT06764875 · 840 planned · United States, Argentina, Australia and more
- Mar 11, 2025Phase 3 study in Endometrial NeoplasmsNCT06989112 · 600 planned · United States, Australia, Austria and more
- Jun 24, 2025Phase 2 study in Stomach NeoplasmsNCT07069712 · 100 planned · United States, Canada, China and more
- Oct 22, 2026Primary completion moved from 2026-11-11 to 2027-05-03Date moved laterphase 3 · +6 months · NCT04784715
Ahead
- Feb 10, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06271837
- Mar 23, 2027Primary completion: phase 2 study in Pancreatic NeoplasmsNCT04482309
- May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT04784715
- May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT04379596
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 21 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07069712Stomach Neoplasms · United States, Canada, China and more | 2 | Recruiting | Nov 9, 2027 | 100 |
| NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Jan 19, 2029 | 600 |
| NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more | 3 | Recruiting | Apr 27, 2029 | 840 |
| NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Jun 12, 2028 | 620 |
| NCT06429761Breast Neoplasms · India | 4 | Active, not recruiting | Oct 31, 2026 | 100 |
| NCT06271837Breast Neoplasms · China | 2 | Active, not recruiting | Feb 10, 2027 | 127 |
| NCT05246514HER2-mutant Non-Small Cell Lung Cancer · China | 2 | Active, not recruiting | Nov 4, 2024 | 72 |
| NCT05113251Breast Neoplasms · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | Mar 12, 2025 | 927 |
| NCT05048797Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 3 | Active, not recruiting | Jun 9, 2026 | 454 |
| NCT04989816Adenocarcinoma · China | 2 | Completed | Jun 16, 2023 | 95 |
| NCT04784715Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | May 3, 2027 | 1,157 |
| NCT04739761Breast Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Feb 8, 2024 | 506 |
| NCT04686305Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 1 | Recruiting | Jun 30, 2027 | 304 |
| NCT04639219Neoplasm Metastasis · United States, Belgium, Canada and more | 2 | Active, not recruiting | Jan 25, 2023 | 102 |
| NCT04556773Breast Neoplasms · United States, Australia, Belgium and more | 1 | Active, not recruiting | Aug 16, 2023 | 138 |
| NCT04538742Breast Neoplasms · United States, Australia, Brazil and more | 2 | Active, not recruiting | Jan 31, 2025 | 245 |
| NCT04494425Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 18, 2024 | 866 |
| NCT04482309Pancreatic Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | Mar 23, 2027 | 477 |
| NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more | 2 | Active, not recruiting | May 4, 2027 | 452 |
| NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more | 2 | Active, not recruiting | Nov 29, 2024 | 243 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | Sep 13, 2024 | 528 |
How it is read
Names in the registry
- “Trastuzumab deruxtecan”, 22 entries
- “Trastuzumab Deruxtecan”, 10 entries
- “DS-8201a”, 7 entries
- “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
- “T-DXd”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 19 studies
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Stomach Neoplasms, 5 studies
- Neoplasm Metastasis, 4 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.